Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis.

Suppr

超能文献

作者信息

López-Vilella Raquel, Trenado Víctor Donoso, Cervera Borja Guerrero, Sánchez-Lázaro Ignacio, Bonet Luis Almenar

机构信息

Hospital Universitari i Politècnic La Fe, Valencia, Spain.

出版信息

Eur J Intern Med. 2022 Oct;104:128-130. doi: 10.1016/j.ejim.2022.06.008. Epub 2022 Jun 27.

DOI:10.1016/j.ejim.2022.06.008

PMID:35773170

Abstract

摘要

相似文献

Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis.

Eur J Intern Med. 2022 Oct;104:128-130. doi: 10.1016/j.ejim.2022.06.008. Epub 2022 Jun 27.

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?钠-葡萄糖协同转运蛋白 2 抑制剂与心血管事件保护：临床试验和观察性研究对真实世界患者的适用性如何？

BMJ Open Diabetes Res Care. 2019 Dec;7(1). doi: 10.1136/bmjdrc-2019-000742.

Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。

Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.卡格列净对比非奈利酮对心肾结局的影响：FIDELIO-DKD 探索性事后分析与 CREDENCE 研究结果的比较。

Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336.

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).钠-葡萄糖共转运蛋白 2 抑制剂起始治疗后的心血管结局和风险：来自 EASEL 基于人群的队列研究的结果（真实世界中钠-葡萄糖共转运蛋白 2 抑制剂的心血管结局证据）。

Circulation. 2018 Apr 3;137(14):1450-1459. doi: 10.1161/CIRCULATIONAHA.117.031227. Epub 2017 Nov 13.

Sodium-glucose cotransporter 2 inhibitors in hospitalized heart failure patients: No time like now.

Eur J Heart Fail. 2023 Oct;25(10):1806-1807. doi: 10.1002/ejhf.3022. Epub 2023 Sep 10.

SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death: Clarity and Consistency.钠-葡萄糖协同转运蛋白2抑制剂可降低心力衰竭住院率和心血管死亡风险：明晰性与一致性

J Am Coll Cardiol. 2023 Jun 27;81(25):2388-2390. doi: 10.1016/j.jacc.2023.04.035.

Sodium-glucose cotransporter 2 inhibitors for chronic heart failure: The ultimate solution?

Eur J Heart Fail. 2023 Aug;25(8):1361-1363. doi: 10.1002/ejhf.2942. Epub 2023 Jun 27.

Recommendation for Appropriate Use of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭治疗中合理应用的推荐意见。

Circ J. 2023 Oct 25;87(11):1707-1709. doi: 10.1253/circj.CJ-23-0605. Epub 2023 Sep 22.

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.卡格列净对伴有慢性肾脏病的 2 型糖尿病患者心血管、肾脏和安全性结局的影响：来自 CREDENCE 试验的结果。根据心力衰竭史进行分层。

Am Heart J. 2021 Mar;233:141-148. doi: 10.1016/j.ahj.2020.12.008. Epub 2020 Dec 22.

引用本文的文献

Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂在急性心力衰竭患者中的疗效和安全性：一项系统评价和荟萃分析

Front Cardiovasc Med. 2024 Sep 11;11:1388337. doi: 10.3389/fcvm.2024.1388337. eCollection 2024.

Progress of patients hospitalized with acute heart failure treated with empagliflozin.住院急性心力衰竭患者接受恩格列净治疗的进展。

J Comp Eff Res. 2024 Jun;13(6):e240027. doi: 10.57264/cer-2024-0027. Epub 2024 May 24.

Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction.射血分数降低的急性失代偿性心力衰竭具有预后意义的药物处方的年度变化。

BMC Cardiovasc Disord. 2024 Feb 14;24(1):105. doi: 10.1186/s12872-024-03728-y.

The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest.SGLT-2抑制剂在急性心力衰竭中的治疗作用：从病理生理机制到临床证据，并对相关研究在感兴趣的安全性和有效性终点进行汇总分析

Life (Basel). 2022 Dec 8;12(12):2062. doi: 10.3390/life12122062.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验